All 26 treated patients completed the one-year follow-up after a single dose.
Participants completed a 25-foot walk test in a median 49% less time than before treatment. Of 12 patients who had needed a walking aid for the test, eight no longer needed one at one year. Nine of 26 patients, or 35%, completed the test in under five seconds; 24 of 26, or 92%, remained off ongoing immunotherapy. The release says targeted immune cells had begun returning in 65% of patients while clinical improvements persisted.
The findings were presented at MSToronto26 on October 21, 2026. Kyverna said it intends to complete a rolling Biologics License Application submission in the fourth quarter of 2026. The release does not establish comparative efficacy against another treatment, long-term safety, FDA approval, or outcomes beyond the reported cohort and one-year follow-up.